The decision concerns the time of filing and admissibility of a revocation action at the Central Division when a parallel infringement action is filed at a local division (Art. 33(4) UPCA). Art 33(4) UPCA states that...more
8/25/2023
/ Amgen ,
Amgen v Sanofi ,
Appeals ,
Dismissals ,
EU ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Luxembourg ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Revocation ,
Sanofi-Aventis